摘要
目的:探讨食管鳞状细胞癌(ESCC)癌组织中X线修复交叉互补基因(1XRCC1)、切除修复交叉互补基因1(ERCC1)的蛋白表达与放射治疗疗效及预后的相关性。方法:采用免疫组织化学SP法检测了59例治疗前ESCC组织和23例癌旁组织标本中XRCC1、ERCC1的蛋白表达,结合临床病理特征和随访数据进行分析。结果:XRCC1、ERCC1蛋白主要表达于细胞核,两者表达无明显相关性。XRCC1蛋白在ESCC组织和癌旁组织中的阳性表达率分别为52.5%和13.0%,P=0.001。ERCC1蛋白在ESCC组织和癌旁组织中的阳性表达率分别为33.9%和65.2%,P=0.010。XRCC1蛋白在汉族组和少数民族组阳性表达率分别为72.2%和43.9%,P=0.045。ERCC1蛋白在无淋巴结转移组和有淋巴结转移组阳性表达率分别为48.3%和20.0%,P=0.022。XRCC1表达阴性组的近期放疗有效率为92.9%,较阳性组的80.6%略有升高,P=0.323。ERCC1表达阳性组和阴性组患者的中位生存期分别为13.2个月(95%CI:10.1～16.3)、21.4个月(95%CI:19.1～23.7),P=0.001。多因素分析显示ERCC1表达、病变长度与患者的生存期密切相关,是独立的预后因素(P=0.001、0.037)。结论:XRCC1、ERCC1的蛋白表达情况可能在食管癌的发生中起一定作用。ERCC1的蛋白表达与食管癌的淋巴结转移及放射治疗预后密切相关,其阳性表达是预后不良的标志。
Objective: To analyze the relationship between the protein expressions of X-ray repair cross-complementing 1, excision repair cross complementing 1 and the effect of radiotherapy and prognosis in esophageal squamous cell carcinoma (ESCC). Methods: The protein expression of XRCC1 and ERCC1 in 59 samples of ESCC tissues and 23 adjacent tissues were examined using SP immunohistochemical staining and were analyzed according to the clinic pathologic features and follow-up data. Results: XRCC1 and ERCC1 protein were expressed in the nucleus of tumor cells in ESCC. There were no correlation between the expression of XRCC1 and ERCC1. The positive expression rate of XRCC1 protein in ESCC and adjacent tissues were 52.5% and 13.0%, respectively(P=0.001). The positive expression rate of ERCC1 protein in ESCC and adjacent tissues were 33.9%and 65.2%, respectively(P=0.010). The positive expression rate of XRCC1 protein in the group of Han nation and the group of minority were 72.2% and 43.9%, respectively (P=0.045). The positive expression rate of ERCC1 protein in the negative lymphnode group and positive lymphnode group were 48.3% and 20.0%, respectively (P=0.022). The short-term effect of radiotherapy in the negative-XRCC1 group (92.9%)was higher than that in the positive-XRCC1 group(80.6%), P=0.323. The median survival period and 95 confidence interval in the group of positive expression of ERCC1 and the group of negative expression of ERCC1 were 13.2 months, 10.1～16.3 months, 21.4 months and 19.1～23.7 months, respectively(P=0.001). In multivariate analysis, the expression of ERCC1 and the tumor length were closely correlated with over all survival and were the independent prognostic factor(sP=0.001, 0.037). Conclusion: The protein expression of XRCC1 and ERCC1 may contribute to the risk of developing ESCC. The expression of ERCC1 is closely correlated with the lymphnode metastasis and effect of radiotherapy, and its positive expression is an unfavorable factor for prognosis of ESCC.
引文
[1] Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in esophageal cancer[J]. Eur J Cancer, 2008, 44(1): 54- 60.
[2] Bourguignon, M.H.Gisone P.A.Perez, M.R. et al. Genetic and epigenetic features in radiation sensitivity Part I: cell signaling in radiation response[J]. Euro J Nucl Med Mol Imaging, 2005, 32(2): 229-246.
[3] Thompson LH, West MG. XRCC1 keeps DNA from getting stranded[J]. Mutat Res, 2000, 459(1): 1-18.
[4] Reed E. Nucleotide excision repair and anti-cancer chemotherapy[J]. Cytotech- nology, 1998, 27(1-3): 187-201.
[5]夏锴,沈洪兵. DNA切除修复基因单核苷酸多态性与食管癌易感性的研究进展[J].临床肿瘤学杂志, 2005, 10(3):331-333.
[6] Harima Y, Sawada S, Miyazaki Y, et al. Expression of Ku 80 in cervical cancer correlates with response to radio-therapy and survival[J]. Am J Clin Oncol, 2003, 26(4): 80-85.
[7]祝淑钗,李任,李娟,等.非手术治疗胸段食管癌临床分期与预后关系的初步探讨[J].中华放射肿瘤学杂志, 2004, 13(3):189-192.
[8] Sinicrope F A, Ruan S B, Cleary K E, et al. Bcl-2 and P53 oncoproteins expression during colorectal tumorigenesis[J]. Cancer Res, 1995, 55(2): 237-241.
[9]殷蔚伯,谷铣之.肿瘤放射治疗学(第三版)[M].中国协和医科大学出版社, 2003: 609-610.
[10] Ladiges W, Wiley J, Macauley A. Polymorphisms in the DNA repair gene XRCC1 and age-related disease [J]. Mech Ageing Dev, 2003, 124 (1) : 27-32.
[11] Thompson LH, Brookman KW, JonesNJ, et al. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatic exchange[J]. MolCell Biol, 1990, 10(12): 6160-6171.
[12] Hung RJ, Hall J, Brennan P, et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review [J]. Am J Ep idemiol, 2005, 162 (10): 925-942.
[13] Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma[J]. Cancer Res, 2004, 64(12): 4378-4384.
[14]张文翠,尹立红,浦跃朴,等.修复酶基因多态性与食管癌易感性关系[J].中国公共卫生, 2006, 22(5): 557-558.
[15]刘建伟,雷威,马建欣,等. DNA修复基因XRCC1多态与食管癌TNM分期及区域淋巴结转移的相关性研究[J].中华胸心血管外科杂志, 2006, 22(5): 315-317.
[16] Ferguson HR, Wild CP, Anderson LA, et al. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett’s adenocarcinoma relationship case-control study[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(3): 736-739.
[17] Bindra HS, Siddiqui EA, Pachouri S, et al. XRCC1 codon 399 and ERCC2 codon 751 polymorphism, smoking, and drinking and risk of esophageal squamous cell carcinoma in a North Indian population[J]. Cancer Genetics and Cytogenetics, 2007, 175(2): 91-97.
[18]孙超,王立东,郭瑞锋等. XRCC1基因多态与食管癌的关系[J].上海第二医科大学学报, 2005, 25(7): 761-762.
[19] Yan L, Yanan D, Donglan S, Corso G, et al. Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma[J]. Dis Esophagus, 2009, 22(5): 396-401.
[20] Huang Y, Li L, Yu L. XRCC1 Arg399Gln, Arg194Trp and Arg280His polymer- phisms in breast cancer risk: a meta-analysis [J]. Mutagenesis, 2009 24(4): 331-339.
[21] Szumilo J, Marzec B, Szumilo M, Genetic base of esophageal squamous cell carcinoma susceptibility [J]. Pol Merkur Lekarski. 2009, 26(152): 93-97.
[22] Samuel H.Wilson. Mammalian base excision repair and DNA polymerase beta [J]. Mutat Res, 1998, 407(3): 203-215.
[23]吴库生,霍霞,邵国,等. X射线交叉互补修复基因1多态性与食管癌易感性关系的Meta分析[J].汕头大学医学院学报, 2007, 20(4): 206-212.
[24]吴常娥,武艳芳. DNA修复基因XRCC1在宫颈癌中的表达[J].河南肿瘤学杂志, 2004, 17(6):401-402.
[25]莫丽. DNA修复基因MGMT-XRCC1在食管癌中表达的研究[J].广西医学, 2009, 31(3): 436-438.
[26] Ran Liu, Li-Hong Yin, and Yue-Pu Pu. Reduced Expression of Human DNA Repair Genes in Esophageal Squamous-Cell Carcinoma in China [J]. Journal of Toxicology and Environmental Health, 2005, 68(19): 956-963.
[27] Fernet M, Hall J. Genetic biomarkers of the rapeutic radiation sensitivity [J].DNA Repair (Amst), 2004, 3 (8-9): 1237-1243.
[28] De Ruyck, K, M Van Eijkeren, K.Claes, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and hOGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes [J]. Radial Oncol Biol Phys, 2005, 62: 1140.
[29] Akulevich N M, Saenko V A, Rogounovitch T I, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. [J]. 2009, 16(2): 491-503.
[30] Chetty C, Bhoopathi P, Rao J S, et al. Inhibition of matrix metalloproteinase-2 enhances radiosensitivity by abrogating radiation-induced FoxM1-mediated G2/M arrest in A549 lung cancer cells [J]. Cancer, 2009, 124(10): 2468-77.
[31] Sigurdson AJ, Land CE, Bhatti P, et al. Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan [J]. Radiat Res. 2009, 171(1): 77-88.
[32] Burri R J, Stock R G, Cesaretti J A, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer [J]. Radiat Res, 2008, 170(1): 49-59.
[33]王宜宗. XRCC1 Codon399单核昔酸多态性与鼻咽癌放疗近期疗效的相关性分析[J].苏州大学学报, 2008, 5.
[34] Yoon S M, Hong Y C, Park H J, et al .The Polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy[J]. International Journal of Radiation Oncology Biology Physics, 2005, 63(3): 885-891.
[35]史卫林,李坚,陈萍,等.X-射线对肺癌细胞DNA修复基因XRCC1表达水平的影响[J].江苏大学学报, 2009, 19(2): 157-160.
[36] Sei C.Sak, Patricia Harnden, Colin F.Johnston, et al. APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radio- therapy in Bladder Cancer[J]. Clin Cancer Res, 2005, 11(17): 6205-6211.
[37]谷志远,赵亚力.现代医学分子生物学[M].北京:人民军医出版社, 2004:53-69.
[38] Robertson K A, Bullock H A, Xu Y, et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation [J]. Cancer Res, 2001, 61(5): 2220-2225.
[39] Zdzienicka M Z, vander Schans G P, Natarajan A T, et al. A Chinese hamster ovary cellmutant (EM-C11) with sensitivity to simple alkylating agents and a very highlevel of sister chromatin exchanges [J]. Mutagenesis, 1992, 7(4): 265-269.
[40] Rosell R, Taron M, Aberola V, et al. Genetic testing for chemotherapy in non-small-cell lung cancer [J].Lung Cancer, 2003, 41(S1): S97-102.
[41] Olaussen K A, Dunant A, Fouret P, et al. DNA repair by ERCC1 in no-small-cell lung cancer and cisplatin-based adjuvant chemotherapy [J].N Engl J ed, 2006, 355 (10): 983-991.
[42] Bradbury P A, Marshall A L, Kulke M H, et al. Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer [J]. Clin Oncol, 2007, 25(18): 2511.
[43] Geoffrey L, Ariela L M, Wei Z, et al. Treatment outcomes of advanced esophageal cancer patients and polymorphisms of nucleotide and base excision repair pathway genes [J].Proc Amer Assoc Cancer Res, 2006, 47(1):1331.
[44] H J Jun, M J Ahn, H S Kim, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation [J]. Br J Cancer, 2008, 99(1): 167-172.
[45]吕嘉春,吴中亮,施侣元,等.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生, 2003, 19(7): 780-782.
[46] Cheng L, Sturgis E M, Eicher S A, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck [J]. Cancer, 2002, 94(2): 393-397.
[47]刘晓. ERCC1、ERCC2表达与食管癌、贲门癌临床病理特征和预后的关系研究[J].河北医科大学学报, 2008, 3:18.
[48] Wachters F M, Wong L S, Timens W, et al. ERCC1, hrad51, and BRCA1 protein expression in relation to tumor response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer, 2005, 50(2): 211-219.
[49] Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predict or of survival in resected patients with non-small cell lung cancer [J].Chest, 2005, 127(3): 978- 983.
[50]周彩存,徐妍,苏春霞,等. ERCC1在非小细胞肺癌中表达及其临床意义[J].中国癌症杂志, 2006, 16(8): 622-625.
[51]宋向群,宁瑞玲,罗元,等.肺癌组织中ERCC-1表达对化疗疗效的预测价值[J].中华肿瘤防治杂志, 2006, 13(22): 1709-1711.
[52]郝艳艳,胡雪君,刘云鹏,等. ERCC1、DNA-PKcs蛋白在非小细胞肺癌中的表达与预后的关系[J].中国肺癌杂志, 2008, 11(2): 226-230.
[53]樊青霞,邢国臣.化疗前食管癌组织中ERCC1mRNA检测对化疗疗效的预测价值[J].郑州大学学报(医学版), 2005, 40(1): 64-67.
[54]王会妍,瞿全新.卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究[J].现代妇产科进展, 2006, 15(7): 512-515.
[55] Britten R A, Liu D, Tessier A, Hutchison MJ, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells[J]. Cancer, 2000, 89(5): 453-457.
[56] Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer [J].Clin Cancer Res, 2004, 10(11): 3794-3799.
[57] Leichman L, Lawrence D, Leichman C G, et al. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival [J]. Chemotherapy, 2006, 18(5): 514-524.
[58] Guo, W, Zhao, Y-P, Jiang, Y-G., et al. ZNRD1 might mediate UV irradiation related DNA damage and repair in human esophageal cancer cells by regulation of ERCC1. Diseases of the Esophagus [J]. 2008, 21(8): 730-736.
[59] Ute Warnecke-Eberz, Daniel Vallb?hmer, Hakan Alakus, et al. ERCC1 and XRCC1 Gene Polymorphisms Predict Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer, 2009, 13(8): 1411-1421.
[1] Sanger D R, Van-de-water L, Brown L F, et al. Vascular permeability factor (VPF, VEGF) in tumor biology [J]. Cancer Metastasis Rew, 1993, 12(3-4): 303-324.
[2] Veikkda T, Alitalok K.VEGF, receptors and angiogenesis [J]. Semin Cancer Boil, 1999, 9: 211-220.
[3] McDonnell C O, Harmey J H, Bouchier-Hayes D J, et al. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with esophageal cancer [J].Br J Surg, 2001, 88(8): 1105-1109.
[4] K.E. Hovinga, L.J.A. Stalpers, C. van Bree,et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines–a clue to radioresistance?[J]. Journal of Neurooncology, 2005, 74: 99-103.
[5] Yuichiro Ohnuma, Masaya Toda, Mamoru Fujita, et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression [J]. Bio- medicine﹠Pharmacotherapy, 2009, 63: 136-145.
[6] Dirk Rades, Helmut Golke, Steven E.Schild, et al. Impact of VEGF and VEGF Receptor 1(FLT1) Expression on the Prognosis of Stage III Esophageal Cancer Patients after Radiochemotherapy [J]. Strahlenther Oncol, 2008, 8: 416-420.
[7] Matsuyama T, Nakanishi K, Hayashi T, et al. Expression of hypoxia-inducible factor 1alpha in esophageal squamous cell carcinoma [J].Cancer Sci, 2005, 96(3): 176-182.
[8] Moeller BJ, Dewhirst M W. Raising the bar: how HIF-1 helps determine tumor radiosensitivity [J]. Cell Cycle, 2004, 3(9): 1107-1110.
[9] Sohda M, I shikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1 alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer [J]. Cancer, 2004, 110(6): 838-844.
[10] Garcia-Rarroos M, Pairs F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis [J]. Science, 2003, 300: 1155-1159.
[11]谢莹.代谢酶基因、DNA修复基因多态性与食管癌关系的研究进展[J].环境与职业医学, 2005, 22(2): 172-175.
[12]朱晓玲,张合喜,杜海荣,等. hOGG1 Ser326Cys基因多态性与食管癌及其临床病理特性的关系[J].环境与职业医学, 2009, 26(2):125-128.
[13]张遵真,张勤,吴媚,李娜,衡正昌. 60Coγ射线对hOGG1低表达细胞株放射敏感性的影响[J].中华放射医学与防护杂志, 2006, 26(3):238-241.
[14] Linzer D I, Levine A J. Characterization of a 54K Dalton Cellular SV 40 tumor antigen present in SV402t transformed cells and uninfected embryonal carcinoma cells[J]. Cell, 1979, 17(1): 43-52.
[15] Chikara K, Toshio I, Roppei Y, et al. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma [J]. Hepato Gastro- enterology, 2006, 53(69): 366-371.
[16] Oohira G, Yamada S, Ochiai T, et al. Growth suppression of esophageal squamous cell carcinoma induced by heavy carbonion beams combined with P53 gene transfer [J]. Oncol, 2004, 25 (3): 563.
[17] Fumiko Sunada, Masayuki Itabashi, Hisanao Ohkura, et al. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy [J]. World J Gastroenterology, 2005, 11(36): 5696-5700.
[18] SHEN M R, JONES I M, MOHRENWEISEER H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair gene in healthy humans [J].Cancer Res, 1998, 58: 604-608.
[19] XING D, QI J, MIAO X, et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Cancer, 2002, 100: 600-605.
[20] Fernet M, Hall J. Genetic biomarkers of the rapeutic radiation sensitivity [J]. DNA Repair (Amst), 2004, 3 (8-9):1237-1243.
[21] De Ruyck, K M. Van Eijkeren, K.Claes, et al.Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes [J].Radial Oncol Biol Phys, 2005, 62: 1140.